Health TrialsbyHealthPanel

A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia

ConditionImmune Thrombocytopenia (ITP)
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorEli Lilly and Company

About this trial

The purpose of the phase 1 part of this study was to evaluate how well pirtobrutinib is tolerated and what side effects may occur. The phase 2 part of the study will further investigate efficacy and safety of multiple pirtobrutinib dosages versus placebo.

The study drug will be administered orally in participants with Primary Immune Thrombocytopenia (ITP). Blood tests will be performed to check how much pirtobrutinib gets into the bloodstream and how long it takes the body to eliminate it.

The study will last up to approximately 16 weeks for phase 1 dose-escalation and 28 weeks for phase 2 dose-optimization, excluding screening.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Have a diagnosis of primary ITP, defined as isolated thrombocytopenia not associated with another known disease process

Have documented history of response, defined as 2 or more platelet counts greater than or equal to 50,000/microliter (μL), to at least 1 prior line of therapy. Splenectomy is considered a line of therapy

Have relapsed or treatment-resistant primary ITP, with no available therapies known to provide clinical benefit

Have a platelet count less than 30,000/μL on 2 occasions at least 5 days apart in the 15 days before randomization

Disqualifiers

Have a history of any thrombotic or embolic event within 12 months before screening

Had a transfusion with blood or blood products or plasmapheresis within 14 days (Phase 1) or within 28 days (Phase 2) of randomization

Have significant cardiovascular disease

Have a diagnosis or history of hematologic malignancy

Trial design

Design model

Sequential

Treatments tested in this trial

  • Pirtobrutinib

    Drug

    Administered orally

  • Placebo

    Drug

    Administered orally

Treatment groups

68 Participants
are divided into 3 treatment groups
Group A: Pirtobrutinib Phase 1Experimental treatment 1 intervention
Group B: Pirtobrutinib Phase 2Experimental treatment 1 intervention
Group C: Placebo Phase 2Placebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Phase 1-Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

A summary of TEAEs and SAEs regardless of causality, will be reported in the Reported Adverse Events module

Time frame
Baseline Up to Week 4
2

Phase 1-Dose Limiting Toxicity (DLT) of Pirtobrutinib

DLTs of Pirtobrutinib

Time frame
Baseline Up to Week 4
3

Phase 1-Number of Participants with Treatment-Related Adverse Events as Assessed by Vital Signs: Blood Pressure, Pulse Rate, and Body Temperature

Blood Pressure, Pulse Rate, and Body Temperature

Time frame
Baseline Up to Week 16
4

Phase 1-Number of Participants with Treatment-Related Adverse Events as Assessed by Clinical Lab Tests: Hematology, Clinical Chemistry, Urinalysis, Pregnancy, Hepatitis Serology and Cytomegalovirus (CMV)

Hematology, Clinical Chemistry, Urinalysis, Pregnancy, Hepatitis Serology and Cytomegalovirus (CMV)

Time frame
Baseline Up to Week 16

Secondary outcomes

1

Phase 1-Preliminary Efficacy of Pirtobrutinib

Platelet response rate defined as proportion of participants who achieve at least 2 consecutive platelet counts of greater than or equal to 50 k/μL and an increase from baseline of greater than or equal to 20 k/μL to any time during treatment without the use of rescue medication within 4 weeks prior to the latest elevated platelet count.

Time frame
Day 1 Up to Week 12
2

Phase 1-Evaluate the Extent of Disease Control

Number of cumulative weeks with platelet counts greater than or equal to 50 k/μL by Week 12

Time frame
Day 1 Up to Week 12
3

Phase 1: Pharmacokinetics (PK) of Pirtobrutinib

PK: Plasma Concentrations of Pirtobrutinib

Time frame
Baseline Up to Week 16
4

Phase 2-Assess Additional Efficacy of Pirtobrutinib Versus Placebo

Platelet response rate is defined as the proportion of participants with greater than or equal to 2 consecutive platelet counts greater than or equal to 50 k/μL and an increase of platelet count of greater than or equal to 20 k/μL from baseline to any time during treatment or follow-up without the use of rescue medication or prohibited concomitant medication that may impact efficacy within 4 weeks prior to the latest elevated platelet count

Time frame
Week 14 Up to Week 24

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Eli Lilly and Company

Lead sponsor

Source ClinicalTrials.gov
Apply now